Medicare will only cover Aduhelm for patients enrolled in clinical trials

CMS announced that Medicare is limiting coverage of the controversial Alzheimer’s disease drug Aduhelm to participants who are enrolled in FDA- or NIH-approved clinical trials.
The decision was based on a review that included comments from more than 10,000 stakeholders and more than 250 peer-reviewed documents, CMS said. It is specific to patients who are clinically diagnosed with mild cognitive impairment due to Alzheimer’s disease or mild dementia and a confirmed presence of plaque on the brain.
“I think Medicare made the right decision. It’s pretty clear that the

CMS announced that Medicare is limiting coverage of the controversial Alzheimer’s disease drug Aduhelm to participants who are enrolled in FDA- or NIH-approved clinical trials.
The decision was based on a review that included comments from more than 10,000 stakeholders and more than 250 peer-reviewed documents, CMS said. It is specific to patients who are clinically diagnosed with mild cognitive impairment due to Alzheimer’s disease or mild dementia and a confirmed presence of plaque on the brain.
“I think Medicare made the right decision. It’s pretty clear that the